ViroGates gives notice to convene an Extraordinary General Meeting on 24 November 2023

9.11.2023 12:11:18 CET | ViroGates | Notice to convene extra. general meeting

COMPANY ANNOUNCEMENT - No. 18-2023 - Notice to convene an Extraordinary General Meeting - 09 November 2023

BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, hereby convenes an Extraordinary General Meeting on 24 November 2023 at 10:00.  

The meeting will be at the company's address at Banevænget 13, 3460 Birkerød. The agenda, full proposals, and registration details can be found in the attached document.

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. [phone], email: [e-mail]

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. [phone], email: [e-mail]

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 850 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments, the Abbott Labs Architect™ and Alinity™ instruments and the Beckmann Coulter AU 5800 instrument. ViroGates works with partners to develop solutions for other platforms. ViroGates has recently launched its Point of Care suPARnostic® POC+ product, a platform that uses only a few drops of finger-prick blood instead of plasma for full quantitative suPAR results in less than 20 minutes.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, [phone], [e-mail]

Attachments

• 20231109 - ViroGates comp. ann. 18- EGM.pdf
• 20231109_ViroGates_EGM November 2023_vF.pdf
• VG_Tilmeldings-Fuldmagtsblanket_DK_EGF NOV 2023_V2.pdf
• VG_Tilmeldings-Fuldmagtsblanket_UK_EGF NOV 2023_V2.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases